Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma

Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma

Neuroblastoma, a childhood cancer affecting the sympathetic nervous system, continues to challenge the development of potent treatments due to the limited availability of druggable targets for this aggressive illness. Recent investigations have uncovered that phosphoglycerate dehydrogenase (PHGDH),...

Full description

Bibliographic Details
Main Authors: Chiao-Hui Hsieh, Chen-Tsung Huang, Yi-Sheng Cheng, Chun-Hua Hsu, Wen-Ming Hsu, Yun-Hsien Chung, Yen-Lin Liu, Tsai-Shan Yang, Chia-Yu Chien, Yu-Hsuan Lee, Hsuan-Cheng Huang, Hsueh-Fen Juan
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Computational molecular docking
High-risk neuroblastoma
Phosphoglycerate dehydrogenase
Molecular target therapy
Drug discovery
Metabolic reprogramming
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223012271

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223012271

Similar Items